Johnson Investment Counsel Inc. Grows Stock Position in Danaher Corporation $DHR

Johnson Investment Counsel Inc. boosted its holdings in Danaher Corporation (NYSE:DHR) by 2.9% during the third quarter, Holdings Channel reports. The institutional investor owned 664,705 shares of the conglomerate’s stock after buying an additional 18,744 shares during the period. Danaher makes up 1.1% of Johnson Investment Counsel Inc.’s portfolio, making the stock its 21st biggest holding. Johnson Investment Counsel Inc.’s holdings in Danaher were worth $131,784,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Profund Advisors LLC boosted its position in shares of Danaher by 1.2% in the third quarter. Profund Advisors LLC now owns 8,229 shares of the conglomerate’s stock worth $1,631,000 after acquiring an additional 96 shares during the last quarter. Oppenheimer Asset Management Inc. raised its stake in Danaher by 2.7% during the third quarter. Oppenheimer Asset Management Inc. now owns 163,134 shares of the conglomerate’s stock worth $32,343,000 after purchasing an additional 4,350 shares during the period. German American Bancorp Inc. raised its stake in Danaher by 3.1% during the third quarter. German American Bancorp Inc. now owns 18,765 shares of the conglomerate’s stock worth $3,720,000 after purchasing an additional 560 shares during the period. Fullcircle Wealth LLC boosted its holdings in shares of Danaher by 24.7% in the 3rd quarter. Fullcircle Wealth LLC now owns 4,069 shares of the conglomerate’s stock valued at $870,000 after purchasing an additional 807 shares during the last quarter. Finally, Azzad Asset Management Inc. ADV grew its stake in shares of Danaher by 5.9% during the 3rd quarter. Azzad Asset Management Inc. ADV now owns 15,653 shares of the conglomerate’s stock valued at $3,103,000 after buying an additional 877 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

DHR has been the topic of a number of research analyst reports. JPMorgan Chase & Co. lifted their target price on Danaher from $270.00 to $275.00 and gave the company an “overweight” rating in a report on Thursday, January 29th. Leerink Partners raised their price objective on Danaher from $260.00 to $270.00 and gave the stock an “outperform” rating in a report on Friday, January 16th. Argus set a $265.00 target price on Danaher in a report on Wednesday, January 14th. Barclays increased their target price on shares of Danaher from $225.00 to $250.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 22nd. Finally, Morgan Stanley started coverage on shares of Danaher in a research note on Monday, December 1st. They set an “overweight” rating and a $270.00 price objective for the company. Twenty equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and a consensus price target of $253.86.

Insider Activity

In other Danaher news, Director Teri List sold 3,298 shares of Danaher stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total transaction of $746,997.00. Following the sale, the director directly owned 20,762 shares in the company, valued at $4,702,593. The trade was a 13.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Brian W. Ellis sold 21,776 shares of the stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total value of $4,773,952.48. Following the transaction, the senior vice president owned 14,553 shares of the company’s stock, valued at approximately $3,190,454.19. This trade represents a 59.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 11.20% of the stock is owned by company insiders.

Danaher Stock Up 0.0%

NYSE DHR opened at $216.65 on Tuesday. The company has a quick ratio of 1.51, a current ratio of 1.87 and a debt-to-equity ratio of 0.35. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $242.80. The business has a 50 day moving average price of $229.47 and a two-hundred day moving average price of $215.27. The stock has a market cap of $153.03 billion, a PE ratio of 42.99, a P/E/G ratio of 2.93 and a beta of 0.91.

Danaher (NYSE:DHR) last posted its earnings results on Wednesday, January 28th. The conglomerate reported $2.23 EPS for the quarter, topping analysts’ consensus estimates of $2.14 by $0.09. The business had revenue of $6.84 billion for the quarter, compared to analysts’ expectations of $6.79 billion. Danaher had a net margin of 14.71% and a return on equity of 10.81%. The business’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same period in the previous year, the company posted $2.14 earnings per share. Danaher has set its FY 2026 guidance at 8.350-8.500 EPS. As a group, sell-side analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, January 30th. Stockholders of record on Friday, December 26th were paid a dividend of $0.32 per share. The ex-dividend date was Friday, December 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. Danaher’s dividend payout ratio (DPR) is currently 25.40%.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.